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I. INTRODUCTION
The way in which medicine is practiced changes almost daily thanks
to emerging technologies. Today, "telemedicine" allows a physician to
treat a patient who is halfway across the country-or even halfway around
the world. Within the broad category of telemedicine, a host of subfields
are emerging. Many medical specialties and services are now developing
and offering services via video conferencing and the use of communica-
tions technology. Teleradiology, teleimaging, telerobotics, teleoperation,
telepsychiatry, telepresence, teleorthopedics, teledermatology, and tele-
health' are just some of the specialties using advanced telecommunications
technology to provide medical care. Entire health care systems and provid-
ers are now using telemedicine. For example, Iowa has a virtual hospital
and Singapore created a cyberspace hospital.2
Telemedicine promises to benefit everyone involved in the provision
of medical care: doctors, patients, health care providers, hospitals, and in-
surers.3 For example, it benefits doctors by lowering the risk of malprac-
tice since telemedicine allows quick and easy consultation with other doc-
tors. Great potential exists for the use of telemedicine in training and
educational contexts.4 In addition, doctors can greatly expand their poten-
tial patient base once they are no longer limited by geography. With health
care professionals on both ends of a telemedicine transaction, telemedicine
will improve treatment and provide better overall care, benefiting the pa-
- 5 •
tients. Patients in rural areas gain access to specialists and treatments that
6
currently are only readily available in metropolitan areas. Telemedicine
1. Claire B. Mailhot, Telepresence: What Is It?, 27 NURSING MGMT. 321 (1996);
Treatment in the Video Age: Televised Visits May Help Patients Who Can't Get There in
Person, BEHAVIORAL HEALTH TREATMENT, Aug. 1996, at 1.
2. Liam J. Donaldson, From Black Bag to Black Box: Will Computers Improve the
NHS?, 312 BRIT. MED. J. 1371 (1996).
3. Senate Approves Bill Designed to Remove Barriers to Telemedicine, 5 Health L.
Rep. (BNA) 910 (June 13, 1996).
4. Chappell Brown, Experts' Prognosis: Technology Has Potential as Teaching, De-
cision-Making Aid, ELEC. ENG'G TIMES, Aug. 12, 1996, at 34; Regan Solmo, A High-Tech
Rx, SUCCESSFUL MEETINGS, Sept. 1996, at 103.
5. Robert F. Pendrak & Peter R. Ericson, Telemedicine May Spawn Long-Distance
Lawsuits, NAT'L UNDERWRITER LIFE & HEALTH-FIN. SERVS., Sept. 30, 1996, at 17, 17.
6. NIIT Update: Denver Health and Hospitals Link Rural Areas, HEALTH MGMT.
TECH., May 1996, at 38, 38.
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can also save time in delivering patient care,7 particularly in emergency
situations. 8
Organizations that reimburse for health care expenses are perhaps the
largest potential beneficiaries of telemedicine. The cost savings, especially
long-term, are phenomenal. Some commentators estimate the cost of
health care can be reduced by 36 billion dollars a year through the use of
telemedicine.9 Telemedicine removes commuting and transportation costs
of both doctor and patient, reduces duplication of tests and records, makes
claim processing more efficient and cost effective, and reduces other ad-
ministrative costs and delays.
While telemedicine promises great benefits, it also creates many so-
cietal, technological, and legal obstacles. Patients will have to be reedu-
cated and given a chance to adjust to a new type of treatment. Many people
may not feel comfortable being diagnosed by a doctor who is hundreds of
miles away.' The initial investment in equipment can also be substantial,
with quoted start-up costs averaging $134,378 to $287,503,'1 depending on
how advanced the equipment is and its applications. Start-up costs can be
reduced somewhat by using "off the shelf' systems rather than custom-
made systems. 12 After the initial investment there are also fees for trans-
mission and maintenance, which average anywhere from $18,573 to
$80,068 annually. 3 Equipment compatibility is a basic requirement, often
difficult and expensive to achieve.
The legal issues involved in developing, operating, and maintaining a
telemedicine system are endless. Maintaining the security of these sys-
tems, as well as protecting the patient's privacy, are major concerns that
now are being addressed. Patients are unlikely to embrace telemedicine
7. Anthony Birritteri, Technology: A Prescription for Speedy Recovery, N.J. Bus.,
Oct. 1996, at 48.
8. Terese Hudson, When Every Second Counts, Hosp. & HEALTH NETWORKs, Sept. 5,
1996, at 61; Leslie Sandberg, Northern California Rates a 'TENN', HALTH MGMT. TECH.,
June 1996, at 17.
9. Use of Medical Technology Blocked by State Regulations, 3 Health L. Rep. (BNA)
1354 (Sept. 29, 1994); Douglas D. Bradham et al., The Information Superhighway and Te-
lemedicine: Applications, Status and Issues, 30 WAKEFORESTL. REv. 145, 147 (1995).
10. Mailhot, supra note 1, at 32K.
11. JOiNT WORKING GROUP ON TELEMEDICINE, REPORT TO CONGRESS pt. ll.G. (Jan. 31,
1997) <http://www.ntia.doc.gov/reports/telemed/index.htm> [hereinafter TELEMEDICNE
REPORT].
12. Telemedicine systems can be custom-made by manufacturers and tailored to suit a
specific medical practice or need, or they can be created "off the shelf' by literally going to
vendors and purchasing separate components intended for use in a variety of applications
and then building the system from the various components.
13. TELEWMDICINEREPORT, supra note 11, pt. II.G.
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without assurances of confidentiality.14 Reimbursement by insurers is a
major barrier to widespread use of telemedicine. Many insurers, including
Medicare and Medicaid, will only reimburse for services provided with a
face-to-face encounter between the doctor and patient.' 5 Because a large
percentage of medical expenses are paid by insurers rather than the pa-
tients themselves, insurers' refusal to pay for telemedicine will sharply
curtail its use. Doctors will be hesitant to use the new technology for fear
of nonpayment.
Physician licensing and malpractice liability are also barriers to tele-
medicine.16 Because telemedicine does not recognize state boundaries, it
creates the problem of a physician practicing in a state where she is not li-
censed 17 or covered by malpractice insurance. Issues of jurisdiction and li-
ability for mistransmission of data are also concerns that must be resolved
prior to the widespread use of telemedicine. Governments are taking steps
to address a number of these issues, mainly through legislation, and often
on the state level. 8
The complex problems and vast benefits created by telemedicine
make it likely that the federal government will step in to regulate the field.
If the federal government attempts to regulate telemedicine, the question
will become: who will be in charge of creating the rules? The Federal
Communications Commission (FCC or Commission), and the Food and
Drug Administration (FDA) under the authority of the Food, Drug and
Cosmetics Act (FDCA) are likely to be the key agencies involved since
telemedicine involves both communications technology and medical tech-
nology. Of course numerous other agencies could assert jurisdiction, in-
cluding, but not limited to: the Consumer Product Safety Commission, the
Occupational Health and Safety Administration, and the Department of
Health and Human Services. 9
This Note discusses the potential jurisdiction of and attempts by one
14. Bradham, supra note 9, at 161; see also Use of Medical Technology Blocked by
State Regulations, supra note 9.
15. John Bennett, Weighing the Costs and Benefits of Telepsychiatry, BEHAV. HEALTH
TREATMENT, Aug. 1996, at 5; Use of Medical Technology Blocked by State Regulations,
supra note 9.
16. Kathleen M. Vyborny, Legal and Political Issues Facing Telemedicine, 5 ANN.
HEALTHL. 61, 66 (1996).
17. Id.
18. Senate Approves Bill Designed to Remove Barriers to Telemedicine, supra note 3;
Jeanne Schulte Scott, State Responses to Telemedicine Licensing Issues, HEALTHCARE FIN.
MGMT., Dec. 1996, at 48, 48.
19. Gary E. Gamerman, Intended Use and Medical Devices: Distinguishing Nonmedi-
cal "Devices" from Medical "Devices" Under 21 U.S.C. § 321(h), 61 GEO. WASH. L. REv.
806, 826-29 (1993).
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of these agencies, the FDA, to regulate telemedicine as a medical device.20
Part II looks at current definitions of telemedicine and the types of appli-
cations included in telemedicine. Part HI discusses the definition of a
medical device, the FDA's regulatory scheme for medical devices, and the
FDA's current stance on regulation of telemedicine systems. Part IV ex-
amines issues raised by FDA regulation of telemedicine and the impact
such regulation will have on telemedicine and related industries, particu-
larly the communications industry.
II. WHAT IS TELEMEDICINE?
Half the battle in dealing with this new genre of patient care is de-
fining telemedicine and determining what telemedicine encompasses.
Many definitions are used, but most of the definitions tend to be rather
broad. In formulating a general definition of telemedicine and in under-
standing the range of services telemedicine encompasses, it is helpful to
look at some of the applications and their common factors.
A. Applications of Telemedicine
The potential applications of telemedicine are limitless. Everything
from 911 emergency service21 to surgery performed by a doctor miles22 .. 23
away to Web sites containing information on disease prevention has
been labeled "telemedicine." Some current applications include: sharing of
patient information and records to save time and administrative costs; 24 ki-
osks set up in urban areas allowing people access to basic healthcare? use
in prisons to insure physician safety when treating inmates;26 use by the
military to treat personnel at sea and in distant locations;27 home monitor-
ing of the elderly and disabled;2 education and training; 29 and providing
20. 21 U.S.C. § 321(h) (1994).
21. Robert Bellinger, Report Proposes Rxfor Telemedicine, ELEC. ENG'G TIMEs, Nov.
11, 1996, at 117, 117.
22. Mailhot, supra note 1, at 321.
23. John Morrisey, Med Center, School Finalists for Award, MODERN HEALTHCARE,
Dec. 2, 1996, at 62, 62.
24. Denise Pappalardo, Networked Medicine, Sprint Helps Hospitals Redefine Health-
care, TELEPHONY, Oct. 7, 1996, at 92.
25. Joshua Dean, In New Jersey, the Doctor Is In-teractive, GOVERNING MAG., Jan.
1997, at 43, 43.
26. Most Active Videoconferencing, ELEC. DEsIGN, Dec. 16, 1996, at 64FF.
27. Treatment in the Video Age: Televised Visits May Help Patients Who Can't Get
There in Person, supra note 1.
28. Bellinger, supra note 21.
29. Brown, supra note 4.
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health care to residents of rural areas.3 ° Another application is computer
diagnostic systems, often called medical expert systems (MES), which use
one central computer to provide diagnostic information, calculations, and
assessments to other remote users. However, all the potential uses have
one common element: the use, in one way or another, of communications
services and technology to transmit information from one place to an-
other.3
B. General Definitions of Telemedicine
Creating a definition that would include all potential applications, or
alternatively, determining which applications should be excluded is not
easy. Overly broad definitions include any medical application that uses
communications technology in any way, regardless of the small part such
technology plays. For example, a phone conversation with a doctor is not
what many people envision when thinking of telemedicine; yet, communi-
cations technology is used to help provide medical care. On the other hand,
almost everyone would agree that a physical examination of a patient by a
doctor miles away, using video conferencing and advanced technology is
telemedicine. Yet determining where the line should be drawn-which ap-
plications should be considered telemedicine-is a difficult task.
The California Senate defined telemedicine as "the use of informa-
tion technology to deliver medical services and information from one lo-
cation to another. ' 32 Telemedicine has also been defined as "the use of in-
formation and communications technologies to provide and support health
care where distance separates the participants, "medical diagnosis and
treatment via telecommunications," and the European Commission de-
fines it as "rapid access to shared and remote medical expertise by means
of telecommunications and information technologies, no matter where the
patient or relevant information is located. 35
The Joint Working Group on Telemedicine (Working Group), an in-
teragency group headed by the Department of Health and Human Services,
36has created "working definitions" for telemedicine and telehealth. Tele-
30. Sandberg, supra note 8.
31. Mailhot, supra note 1.
32. Telemedicine Development Act, 1996 Cal. Legis. Serv. Ch. 864, § 1 (West) (S.B.
1665).
33. Bellinger, supra note 21, at 117.
34. Vyborny, supra note 16, at 61.
35. Patrick Hook, Skyhigh Healthcare: Airlines Are Finally Considering Fitting Tele-
medicine Equipment, FLIGHT INT'L, Aug. 21-27, 1996, at 29, 29.
36. Telemedicine Related Activities (July 11, 1996)
<http://www.fda.gov/cdrh/telemed.html>.
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medicine refers to health care services for individuals, while telehealth
deals with general health care services. The Working Group's definition of
telemedicine is:
The delivery and provision of health care and consultative serv-
ices to individual patients and the transmission of information related
to care, over distance, using telecommunications technologies, and in-
corporating the following activities:
I. Direct clinical, preventive, diagnostic, and therapeutic
services and treatment, including procedures where a pro-
vider may be present with the patient, and clinical training
and consultative clinical Grand Rounds, if used for deci-
sion making regarding the clinical care of a specific pa-
tient.
II. Consultative and follow-up services.
IL. Remote monitoring, including the remote reading and in-
terpretation of results of patient's procedures.
IV. Rehabilitative services.
V. Patient education provided in context of delivering health
care to individuals.1
7
The above definition includes a wide range of applications. It includes the
type of services that many people think of as telemedicine, particularly
video conferencing. But it also includes phone consultation between a
doctor and patient as they discuss test results.
The Working Group's definition excludes certain significant applica-
tions such as numerous Web sites geared toward providing information to
38individuals; currently, these are numerous. In spite of the exclusion of
applications such as Web sites, the Working Group's definition of tele-
medicine is one of the most specific and complete definitions and is the
one used for purposes of this Note.
C. Components Involved in Telemedicine
It is important to consider what elements are included in telemedicine
systems when trying to regulate them. By its nature, telemedicine involves
multiple components and multiple parties. A minimum of three parties will
be involved in any telemedicine transaction: the initiator of the transmis-
sion, the receiver of the transmission, and the communication service pro-
vider. Quite often more parties will be involved. The information may be
transmitted to more than one doctor in more than one location. Addition-
ally, because of the way in which phone service is currently provided, un-
37. Id.
38. Brief descriptions of several of these Web sites can be found at
<http://www.gii-awards.com/finalists/FinHealth.html>.
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less the transmission is within a small geographic area, several service
providers are needed to complete the transmission of the data via modem.
Each party to a telemedicine transaction will have its own equipment, both
hardware and software, all of which could be a device for purposes of FDA
regulation.
The number of components used in telemedicine, which could poten-
tially be regulated by the FDA as medical devices, is tremendous. These
include the hardware used by both the initiator and receiver: the monitors,
video cameras, computers, wires and cables, keyboards, modems, printers,
facsimile machines, and any other equipment used at their locations. In
addition, the communications service provider uses hardware: the phone
lines, cables, telephone poles, fiber optic cable, satellite equipment,
switches, and other equipment which could face regulation as medical de-
vices.
The software used by all the parties is another component in tele-
medicine systems and could potentially be regulated. The end users (both
the initiator and receiver) of the transmission will have several types of
software on their system. At a minimum, users must have some communi-
cations software in order to convert the data or images to digital form and
then transmit them. The companies providing the communications service
will also have their own software to direct the transmissions and deal with
other routine and advanced functions. As part of a telemedicine system, all
of these components are potentially subject to regulation as medical de-
vices by the FDA.39
III. FDA REGULATION OF MEDICAL DEVICES
Prior to 1976, the FDCA allowed the FDA to regulate drugs, but it
40
was not able to regulate medical devices directly. If the FDA wanted to
regulate a medical device it had to first classify it as a drug, and then the
device could be regulated according to the regulations applicable to
drugs.4' This burdensome method of regulating medical devices ended in
1976 with the passage of the Medical Device Amendments of 1976,42
which gave the FDA authority to regulate medical devices directly. The
Safe Medical Devices Act of 19904e supplemented the 1976 Amendments
and attempted to create improved, comprehensive regulation of medical
39. 21 U.S.C. § 321 (h)(1994).
40. Gamerman, supra note 19, at 817-18.
41. Id.
42. Medical Device Amendments of 1976, 21 U.S.C. §§ 360c-360k.
43. Safe Medical Devices Act of 1990, Pub. L. No. 101-629, § 1(a), 104 Stat. 4511,
4511 (1990) (codified in scattered sections of 21 U.S.C. & 42 U.S.C. (1994)).
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devices designed to promote public health and safety.
A. Medical Device Regulation under the 1976 and 1990
Amendments44
The 1976 and 1990 Amendments to the FDCA were intended to al-
low FDA jurisdiction over medical devices to ensure that the device itself
and its use did not pose a risk to the safety or health of the public. The
FDA asserted its jurisdiction and created extensive regulations applicable
to medical devices. Unfortunately, the regulatory scheme proved to be
overly burdensome. In addition to preventing the distribution and use of
unsafe medical devices, the delays in reviewing the required application
documentation prevented the use and distribution of many safe and helpful
medical devices.
1. Defining a Medical Device
The FDCA defines a device at 21 U.S.C. § 321(h) as:
an instrument, apparatus, implement, machine, contrivance, implant, in
vitro reagent, or other similar or related article, including any compo-
nent, part, or accessory, which is
(1) recognized in the official National Formulary, or in the United
States Pharmacopeia, or any supplement to them,
(2) intended for use in the diagnosis of disease or other conditions,
or in the cure, mitigation, treatment, or prevention of disease, in
man or other animals, or
(3) intended to affect the structure or any function of the body of
man or other animals, and which does not achieve its primary
intended purposes through chemical action within or on the body
of man or other animals and
which is not dependent upon being metabolized for the achievement of
its primary intended purposes.
Only one of the three elements listed above must be present to classify an
object as a medical device. This definition is extremely broad and can be
interpreted to cover a vast array of products." In fact, this definition gives
the FDA jurisdiction over almost any device or product used in the medi-
cal field.
The FDA has found many products that are not widely regarded as
44. The following is a very basic, simplified overview of FDA regulation of medical
devices. It is not meant to be comprehensive, but merely to give a quick glance at some of
the main provisions.
45. 21 U.S.C. § 321(h).
46. Committee of Dental Amalgam Mfrs. and Distribs. v. Stratton, 92 F.3d 807, 810
(9th Cir. 1996).
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devices intended for medical purposes to be medical devices under §
321(h). Such products include an E-meter (a polygraph-like device used by
the Church of Scientology allegedly to cure disease),47 a vinyl-covered bed
4' 
48with speakers mounted on the sides, and phonograph records.49 The FDA
has also regulated devices that never have any direct contact with patients,
such as laboratory specimen collection containers50 and surgical instrument
sterilizers.5'
The courts found that in determining whether a device qualifies as a
medical device for regulatory purposes, first the court "must give broad
deference to the FDA's reasonable interpretation of the statutory scheme
that it is entrusted to administer. 52 Additionally, no direct contact with
patients was necessary for an item to be a device. "Indeed, even device
'accessories' and 'components' intended for use in devices standing alone,
constitute devices."53 The court stated:
[T]he Supreme Court noted that Congress intended products
"such as electric belts, quack diagnostic scales, and therapeutic lamps,
as well as bathroom weight scales, shoulder braces, air conditioning
units, and crutches" to be devices. The inclusiveness of such items as
devices reflects Congress' clear intent to characterize "basic aids used
in the routine operation of a hospital.. ." as devices.
54
One Senator lamented "[t]he language [of the bill] is broad enough to
cover any device of which the Food and Drug Bureau of the Agricultural-- . .. ,,55
Department chooses to take jurisdiction. The courts have generally
given broad discretion to decisions of the FDA as to the devices subject to
regulation under § 321(h).
Most medical devices fall under § 321(h)(2) as "intended for use in
the diagnosis... cure, mitigation, treatment, or prevention of dis-
ease .... 56 Almost any of the components of a telemedicine system couldfall under this provision. After all, the purpose of telemedicine is to allow
47. United States v. Article or Device, "Hubbard Electrometer", 333 F. Supp. 357
(D.D.C. 1971).
48. United States v. One Labeled Unit, 885 F. Supp. 1025 (N.D. Ohio 1995).
49. United States v. 23, More or Less, Articles, 192 F.2d 308 (2d Cir. 1951).
50. Clinical Reference Lab., Inc. v. Sullivan, 791 F. Supp. 1499 (D. Kan. 1992).
51. United States v. 22 Rectangular or Cylindrical Finished Devices, 714 F. Supp. 1159
(D. Utah 1989).
52. Clinical Reference Lab., 791 F. Supp. at 1509.
53. 22 Rectangular or Cylindrical Finished Devices, 714 F. Supp. at 1164.
54. Id. at 1164 n.12 (quoting United States v. Article of Drug, Bacto-Unidisk, 394 U.S.
784, 800 (1969)).
55. United States v. 25 Cases, More or Less, of an Article or Device, 942 F.2d 1179,
1182 (7th Cir. 1991) (alterations in original).
56. 21 U.S.C. § 321(h)(2) (1994).
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for the treatment, diagnosis, or prevention of disease using communica-
tions services to connect the doctor and patient. It is not much of a jump
for the FDA to attempt to regulate telemedicine systems either as a whole
or to regulate parts of such systems. The broad definition of a medical de-
vice in § 321(h) would allow regulation of virtually any part of a telemedi-
cine system, including communications equipment and services.
2. Classifying Medical Devices
Once an item is found to be a device under § 321(h), it must be clas-
sified. The FDA places devices into one of three categories based upon the
level of risk they create to the health and safety of both the patients and
• 57
health care providers. Class I is the classification applicable to devices
creating the lowest risk, therefore subject to the least regulation. The
general controls for Class I devices are applicable to all devices regardless
of their classification. 60 Devices placed in Class II create more risk than
those in Class I and are subject to additional controls to ensure their
61 62
safety. Most medical devices are placed in Class II. Class HI devices
pose the greatest risk, requiring the most scrutiny, including premarket ap-
proval by the FDA. 6' All new devices that are not substantially equivalent
to a device existing prior to the 1976 amendments are automatically placed
into Class H1.6'
a. Class I Devices
The Class I general controls are applicable to all medical devices.
They include requirements placed on adulterated devices; 65 requirements66 - 67
for misbranded devices;66 registration; inspection of premises require-
57. Frank D. Nguyen, Regulation of Medical Expert Systems: A Necessary Evil?, 34
SANTA CLARA L. RaV. 1187, 1205 (1994); 21 U.S.C. § 360c(c).
58. Nguyen, supra note 57, at 1206. Devices placed in Class I include "tongue depres-
sors, elastic bandages, ice bags, and bedpans." Id.
59. 21 U.S.C. § 360c(a)(1)(A) (1994).
60. Nguyen, supra note 57, at 1206.
61. 21 U.S.C. § 360c(a)(1)(B).
62. Nguyen, supra note 57, at 1206. "Class II devices include syringes, bone plates,
hearing aids, resuscitators, and electrocardiograph electrodes." Id.
63. 21 U.S.C. § 360c(a)(1)(C); Nguyen, supra note 57, at 1206. Examples of Class IH
devices are "pacemakers, intra-uterine contraceptive devices (IUDs), artificial hearts, and
artificial joints." Id.
64. 21 U.S.C. § 360c(f)(1).
65. Id. § 351.
66. Id. § 352.
67. Id. § 360(b).
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68 6970
ments; 8 listing of devices manufactured;' 9 premarketing notification; no-
tification of risk to purchasers and users of the device;7' reporting of ad-
verse effects of the device;72 and good manufacturing practice require-
ments.73
While this is a very simplified glance at the Class I requirements, the
effect of the above requirements on manufacturers of telemedicine devices
or systems can still be seen. Particularly, the requirement that notice be
given to the FDA prior to marketing of such systems or certain compo-
nents of the system intended for use in telemedicine will deter companies
from developing and marketing such devices. Additionally, compliance
with the good manufacturing requirements and premises inspection re-
quirements may call for such a change in the way businesses manufacture
that it will not be economically feasible for them to comply. Rather, busi-
nesses will simply not market their components and systems for use in a
telemedicine context.
b. Class H Devices
Class II devices are subject to additional regulations beyond the gen-
eral controls for Class I devices. The special controls or performance stan-
dards for Class II devices can include "promulgation of performance stan-
dards, postmarket surveillance, patient registries, development and
dissemination of guidelines,.., recommendations, and other appropriate
actions as the Secretary deems necessary to provide [reasonable] assurance
[of the safety and effectiveness of the device]."74 Rather than being gener-
ally applicable to all Class II devices, these special controls are often im-
posed on a device-by-device basis.75 Due to the large number of devices in
Class I,76 the process of issuing standards for all Class II devices is
daunting. Administrative regulations for classifying devices further hinder
the process.77 Consequently, few performance standards for Class II de-
vices have been issued."' This in practice eliminates the distinction be-
68. Id. § 360(h).
69. Id. § 360(j).
70. Id. § 360(k).
71. Id. § 360i.
72. Id. § 360h.
73. Id. § 360j.
74. Id. §§ 360c(a)(1)(B), 360d(a)(1).
75. Nguyen, supra note 57, at 1207.
76. David A. Kessler et al., The Federal Regulation of Medical Devices, 317 NEW ENG.
J. MED. 357, 361 (1987).
77. Id.
78. Id.
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tween Class I and Class H devices because until Class 11 standards are cre-
ated, compliance with the general Class I standards is all that is required.
79
c. Class Ifi Devices
Premarket approval (PMA) is required for all Class I devices. Pre-
market approval requires the manufacturer to file an application showing• 80
that the device is safe and effective; describing the components and prop-
erties of the device;"' the methods used in manufacturing and packaging
the device;s2 and the proposed labeling for the device.8' Additionally, PMA
allows only that particular applicant to market the device.84 If another
manufacturer desires to market its own version of the same device, it must
go through the PMA process anew for its version of the device.5 The FDA• 86
is required to act on applications for PMA within 180 days of receipt.
However, in practice the process takes approximately one year. 7
The long delay in obtaining PMA for telemedicine systems and/or
their components will severely hinder the development and application of
telemedicine. As rapidly as communications technology changes, a one-
year delay in receiving PMA is equivalent to an eternity. Manufacturers
cannot sell any Class I device or system until the device has received
PMA. If forced to wait a year or longer for approval, the technology that
the approved system was based on may become obsolete and uneconom-
ical to produce. Without an economic incentive to produce these systems
and components, manufacturers will withdraw from the market, to the det-
riment of telemedicine.
B. Current FDA Attempts at Regulation of Telemedicine Systems
and Components
The FDA has provided no clear guidance regarding the role it will
take in the regulation of telemedicine systems. Thus far the FDA has made
no attempts to regulate telemedicine systems as a whole, and has done
relatively little to regulate the individual components of such systems, be-
79. Id.
80. 21 U.S.C. § 360e(c)(A) (1994).
81. Id. § 360e(c)(1)(B).
82. Id. § 360e(c)(1)(C).
83. Id. § 360e(c)(1)(F).
84. Kessler, supra note 76, at 359.
85. Id. There are limited exceptions to this rule; most significantly, manufacturers are
allowed to use data from other PMA applications once it has been accepted by the medical
community.
86. 21 U.S.C. § 360e(d)(1)(A).
87. Kessler, supra note 76, at 359.
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S• 88yond regulating "traditional" medical devices used in telemedicine. The
lack of guidance from the FDA poses a huge problem for those developing
such systems, for those manufacturing components of the systems, and for
those health care providers purchasing a system-only to later find out it
does not comply with newly created FDA regulations. The problem of
compliance with FDA regulations may also arise because many of the
systems used today are "adaptations of existing teleconferencing or desk
top computer systems which were originally designed for purposes other
than health care delivery."89 It is unlikely that a computer manufacturer
will be willing to change its manufacturing process and procedures to
comply with FDA regulation of a manufacturer's system when the system
was not intended for medical use and can be marketed for numerous other
profitable applications.
Despite the problems of regulating telemedicine, it is unlikely that
the FDA will simply decline to assert jurisdiction over telemedicine. The
Telemedicine Report to Congress states "[w]ith respect to telemedicine,
the FDA is responsible for ensuring the safety and effectiveness of tele-
medicine devices marketed in the United States." 90 The FDA is beginning
to take steps to regulate telemedicine. It has already started to regulate
hardware, specifically teleradiology systems and medical imaging sys-
tems.9' What, if any, regulation other hardware will be subject to remains
unclear.92
A key component or area that the FDA is beginning to regulate is
software used in telemedicine systems. However, exactly what is regulated
and to what extent is unclear. Several draft policies have been issued, but
they do not have the force of regulations.93 The policies have recognized
some software as medical devices.94 Other software is currently regulated
on an ad hoc basis.95
88. These "traditional" medical devices include those devices which are merely hooked
into the telemedicine system or used during the telemedicine consult, but would also be
used in a regular face-to-face consultation. Some such devices are: stethoscopes, an EKG
machines, heart monitors, and x-ray machines.
89. TELEMEDICINE REPORT, supra note 11, pt. V.A.
90. Id.
91. COUNCIL ON COMPETITIVENESS, HIGHWAY TO HEALTH: TRANSFORMING U.S.
HEALTHCARE IN THE INFORMATION AGE (Mar. 1996)
<http://nii.nist.gov/pubs/cochghwy.tohlth/hii.txt> [hereinafter HIGHWAY TO HEALTH].
92. Id.
93. Id.
94. Center for Devices and Radiological Health, FDA, Software Policy Workshop:
FDA Regulation of Medical Device Software (Sept. 3-4, 1996) (points prepared for discus-
sion available at <http://www.fda.gov/cdrh/ost/points.html>).
95. Center for Devices and Radiological Health, FDA, Software Policy Workshop:
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If the FDA uses the traditional approach to medical device regulation,
it has the option of simply labeling the software as a general purpose de-
vice; as such the software is not subject to regulation.9 In an FDA software
policy workshop, several examples falling into this category of general
purpose devices included programs controlling computer hardware that
were not specifically designed for medical applications, as well as "off-
the-shelf' software such as word processing programs and database pro-
grams.97 The communications software used in most telemedicine systems
was not designed for a medical application and would seem to fall into the
category of general-purpose devices.
Alternatively, it has been suggested that if the software is an acces-
sory, used in conjunction with another device regulated by the FDA as a
medical device, the software could be subject to the same level of regula-
tion as the associated device. This seems to indicate that communications
software used as part of a telemedicine system could be subject to FDA
regulation if it is found to be an accessory to another regulated device. For
example, communications software could be viewed as an accessory to
traditionally regulated devices, such as radiology equipment. The software
could enhance the equipment by allowing the images to be transmitted via
wire lines to a remote physician. Thus, the software becomes an accessory
to the radiology equipment, and the FDA can regulate the communications
software.
In its Guidance for the Content and Review of 510(K) Notifications
for Picture Archiving and Communications Systems (PACS) and Related
Devices (Guidance for PACS), the FDA, through the Center for Devices
and Radiological Health, seems to include communications software as a
medical device subject to regulation. The document begins by stating
"[t]his guidance is applicable to picture archiving and communications
systems (PACS). PACS are systems which are intended to provide trans-
mission, storage and viewing facilities for medical diagnostic images at
distributed locations." 99 In essence, PACS are the "linchpin" of many te-
lemedicine systems,l ° and the Guidance for PACS seems to indicate that
Classification and Risk-Based Criteria (Sept. 3-4, 1996) (points prepared for discussion
available at <http:/www.fda.gov/cdrhlostlclassif.html>).
96. Id.
97. Id.
98. CENTER FOR DEVICES AND RADIOLOGICAL HEALTH, FDA, GUIDANCE FOR THE
CONTENT AND REVIEW OF 510(K) NoTIFcAnONS FOR PICTURE ARCHIVING AND COM-
MUNICATIONS SYSTEMS (PACS) AND RELATED DEVICES (visited Jan. 30, 1998)
<http://www.fda.gov/cdrhlode/odeot4l6.html> [hereinafter GUIDANCE FOR PACS].
99. Id.
100. TELEMEDICINEREPORT, supra note 11, pt. V.
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PACS systems can and will be regulated as medical devices.
The Guidance for PACS then states that it is also applicable to related
devices that perform functions provided by PACS, including image com-
munications equipment, both networks and interfaces.'O This would give
the FDA jurisdiction to regulate not only communications software but
communications networks as well. This is a frightening proposition for
those developing and maintaining networks and providing communications
services. Confusing the issue further, the document goes on to state:
The guidance does not apply to general purpose devices if they
are not specifically indicated or promoted for use in conjunction with
medical images. These products are not considered to be medical de-
vices and premarket notifications are not required. Examples of such
devices include general purpose communications systems, data storage
media and software. However, if general purpose devices are indicated
or promoted for medical use, a 510 (k) must be submitted. Also, if they
are sold as a PACS component, they must be described in the 510 (k)
for the system. 10
The applicable level of FDA regulation seems to depend on whether
manufacturers indicate or promote the device for medical use. If they pro-
mote it for medical use, then they are subject to the entire gambit of FDA
regulation. If they simply allow their device to be used as a component but
do not promote it for medical use, then the device only needs to be de-
scribed in the required documentation for the PACS system, rather than
being subject to its own separate review. To subject two different manu-
facturers making an essentially identical product, ultimately used in the
same manner in a telemedicine system, to different levels of regulation
based on how they promote their product makes little sense.
Other approaches have been suggested for the regulation of devices
containing software, such as establishing levels of concern and regulating
based upon the level of concern or risk the device creates, rather than the
traditional class system. The FDA drafted such a proposal, and the pro-
posal indicated that some level of scrutiny would be applied to software
regardless of whether it was general purpose software or software designed
for medical uses.103
So far, the FDA has issued no consistent, clearly articulated regula-
tions or policies regarding communications software used in telemedicine
systems. The documents currently available provide little assistance to
those manufacturing or developing telemedicine systems or the software
for such systems. Despite the lack of specific guidance from the FDA, it
101. GUIDANCE FOR PACS, supra note 98.
102. Id.
103. See I-IGHWAY TO HEALTH, supra note 91, ch. 5.
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appears that the FDA has adopted an approach of regulating the individual
telemedicine system components rather than regulating the systems as sin-
gle units or single medical devices. This has important implications for
those involved in creating and developing both the components of such
systems and the systems themselves.
IV. APPROACHES TO FDA REGULATIONS OF TELEMEDICINE
AND THEIR IMPLICATIONS
When evaluating approaches to the regulation of communications
hardware and software used in telemedicine and their implications, it is
important to remember exactly what parts or components are involved in a
telemedicine system. The actual computer hardware and software used to
run the systems at the health care provider's office; the communications
software used by the health care provider; the modems; the video cameras;
the monitors; the specialized medical equipment that is connected to the
system; the communications software used by the communications service
provider (such as AT&T, MCI, and Ameritech); the hardware (copper
lines, fiber-optic cable, satellites, etc.) used by the service provider to
transmit the data; and the method in which the information is sent are each
potentially subject to regulation under the current, broad definition of a
medical device.
The FDA has several options in attempting to regulate telemedicine
systems and components. One is to regulate the systems as a whole or as a
single medical device. But to set out one regulatory scheme or approach
applicable to all the different components within a system is a complex,
virtually impossible task. Some components of a system pose a greater risk
to the safety and health of patients and users than others. Different systems
pose varying levels of risk depending on their applications. Regulations
appropriate for medical software used for telemedicine may not be appro-
priate for the cables transmitting the information to its destination.
Regulating systems as a whole would require the FDA to regulate not
only the communications software and hardware, but also the equipment
used to transmit the data and the manner in which the data is transmitted.
Any regulation would cover the communications service provider's hard-
ware and software as well as the individual communications software used
by the health care provider. It is questionable whether it is desirable for the
FDA to become involved in regulating communications in any aspect, and
the communications companies are unlikely to agree to stricter standards
in their hardware, software, and procedures--especially if it increases their
costs. Rather than incur additional costs related to FDA compliance, manu-
facturers will simply market their communications software and hardware
for other more profitable applications, and withdraw from the telemedicine
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market.
Further, any change in the system could require new approval for the
entire system.' 4 Each time a device is changed, no matter how minor the
change, FDA approval is required.'05 The use of new cable or wire could
place the system behind all of the other devices awaiting FDA approval.
An already backlogged FDA is unlikely to provide quick approval, even
for minor changes.' °6 All of these factors lead to the conclusion that FDA
regulation of telemedicine systems as a whole is not desirable or feasible.
Wisely, the FDA does not appear to be aggressively pursuing this ap-
proach.
A second approach, similar to the current stance taken by the FDA, is
to individually regulate each component of telemedicine systems. This ap-
proach addresses many of the concerns about regulating the systems as
single medical devices. Regulation on a component-by-component basis
allows consideration of the different levels of risk created by the different
components, and allows for varying levels of regulation based on the level
of risk.
This also avoids new FDA approval for the entire system each time
one component is changed. Approval can be sought only for the compo-
nent that is changed. The effect of the change on the entire system can be
documented and submitted, but there is no need to redocument the entire
system for new FDA approval.
The biggest advantage of regulating the components of the system
individually is the possibility of the FDA exempting certain portions of the
systems from FDA regulation. As discussed previously, FDA regulation of
the communications industry is troublesome. This will allow exemption of
communications hardware and software, particularly PACS. The FDA can
continue to regulate those components that are truly medical devices and
are used directly in the diagnostic process. For example, x-ray systems,
CAT Scan systems, and heart monitors would still be regulated by the
FDA. However, those components dealing with other functions, such as
communications, data processing, and management, could be excluded
from FDA regulation. Freeing communications software providers and de-
velopers from potential FDA regulation would encourage their active par-
ticipation in telemedicine projects and would be a huge boost to the devel-
opment of telemedicine. Communications service providers are much
104. See Software CBER Short on Experts, Long on Blood Software 510(k)s, MED.
DEVICE APPROVAL LETTER, July 1, 1996, available in 1996 WL 8642124.
105. HIGHWAY TO HEALTH, supra note 91, ch. 5.
106. See 510(k)s Submitted for Blood Bank Software, MED. DEVICE APPROVAL LETrER,
April 1, 1996, available in 1996 WL 8642107.
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more likely to support telemedicine if their involvement does not impose
additional regulations and costs.
Communications providers will continue to be subject to the regula-
tions imposed by other regulatory agencies, but will not have the addi-
tional burden of FDA regulation. Due to the crucial nature of the data be-
ing transmitted, higher standards may be desirable. However, if such
standards cause the service providers to withdraw from the market, then
the benefits of telemedicine are lost. Any risk of mistransmission or a total
loss of data can be distributed between the parties involved through indi-
vidual contracts allocating the risk. By allocating the risk via contract,
each party will know what their potential liability is and will be able to act
accordingly.
Although regulation on a component-by-component basis is more de-
sirable than regulation of entire telemedicine systems, a component-by-
component approach will work only if the FDA acts reasonably with re-
gard to the components of telemedicine systems over which it attempts to
assert jurisdiction. While initially regulating only "traditional" medical de-
vices, the FDA is increasingly moving toward broader assertions of juris-
diction. As it attempts to regulate more and more aspects of telemedicine
systems and computer software, more problems will arise.
Software manufacturers or developers are in an especially problem-
atic position to deal with FDA regulation. With each new version of the
software, new FDA approval would be necessary. Every change to elimi-
nate a bug in the program could potentially require additional FDA ap-
proval. Requiring essentially continual FDA approval for every change in
the software "'will have a chilling effect on the evolution of software tech-
nology.' ' 10 7 Even if approval is granted in a mere six to seven months, 10'
well within the current time frame of one year, the software will be out of
date upon its approval. Consequently, telemedicine systems will be forced
to use outdated software, often with known and correctable errors, due to
lack of FDA approval of the updated version.
This dilemma and its results can be seen in the context of blood bank
software. Once the FDA asserted jurisdiction over blood bank software
and promulgated regulations, the number of developers and manufacturers
immediately began to decrease. "'Some software developers have already
with drawn [sic] from the blood bank market. They feel it's not that large
of a market for them, and feel that software changes are sort of an evolu-
tionary thing, and that any software upgrade would require a resubmis-
107. Id. (quoting Edward Allera of Akin, Gump, Strauss, Hauer & Feld).
108. Id.
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sion." °9
A similar result is likely to occur in the communications software in-
dustry. As the FDA begins to assert jurisdiction over communications
software used in telemedicine, developers of such software will leave the
market rather than incur the additional costs of compliance with FDA
regulation. This is especially true since communications software has a
multitude of nonmedical applications that do not require compliance with
burdensome regulations.
While it is not apparent that the FDA needs to regulate communica-
tions software to ensure the safety and effectiveness of telemedicine sys-
tems, if it is unwilling to decline jurisdiction, it must take a different ap-
proach to the regulation of communications software. New guidelines
specifically for software must be created. Rather than regulate software
through the traditional scheme now in place for medical devices, software
could be dealt with separately on an expedited basis. Thus the rapid
changes and limited life of software could be taken into account, allowing
telemedicine systems to use updated and current software without awaiting
slow, traditional FDA approval.
V. CONCLUSION
Telemedicine systems and their components fall under the broad
definition of medical devices set out in 21 U.S.C. § 321(h). Technically,
there is nothing to prohibit the FDA from asserting its jurisdiction over te-
lemedicine systems or components. Already the FDA has begun to regu-
late some components of telemedicine systems and is beginning to regulate
PACS and other related communications software.
The current lack of clear guidance on the regulation of communica-
tions software and PACS will hinder the development and use of telemedi-
cine. Clearer policies and guidance on the FDA's approach to telemedicine
systems are essential. Without them, systems manufacturers and develop-
ers will be wary of entering the market, not knowing whether they are in
compliance, and whether they will be subject to penalties for noncompli-
ance.
As the FDA attempts to regulate telemedicine, a decision has to be
made whether to regulate the systems as a whole or as individual compo-
nents. Although the FDA appears to have adopted a reasonable, compo-
nent-by-component approach, it remains to be seen how it will implement
that approach. The FDA's actions on this point will dramatically affect the
future of telemedicine.
109. Id. (quoting Carolyn Jones, HIMA Director of Technology and Regulatory Affairs).
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If the FDA asserts jurisdiction over all components in telemedicine
systems, including communications hardware and software, the results will
be disastrous. As communications services are finally becoming deregu-
lated, the last thing the providers want is to comply with additional FDA
regulations, especially since telemedicine is likely to be a small part of
their overall market. Without communications services, telemedicine is at
a standstill. Maintaining an appropriate balance between regulation to en-
sure safety of telemedicine systems and deregulation of the communica-
tions industry is essential to the future success of telemedicine.

